

(a)
(b)
4DMT Proprietary Libraries
(n = 20+)
(c)
In Vivo Vector Selection:
Stage 1
Vector Hits Identified
(d)
In Vivo Vector Selection:
Stage 2
Vector Hits Identified
(e)
AAV Capsid Variants

FIGURE 1



Left Eye
Right Eye
fovea
vascular arcade
fovea
vascular arcade

FIGURE 2



GCL INL ONL RPE
in mid out in mid out in mid out
GCL INL ONL RPE
in mid out in mid out in mid out

FIGURE 3



(a) Round 3
40.74
7.41
9.26
13.67
12.96
12.96
(b) Round 4
20.00
21.67
11.33
13.33
33.33
(c) Round 5
22.64
5.66
7.08
1.89
11.32
50.94
(d) Round 6
17.74
32.26
50.00
Peptide Insertion #1
Point Mutation #1
Peptide Insertion #2
Point Mutation #2
Peptide Insertion #3
Other

FIGURE 4




FIGURE 5

FIGURE 6A



AAV1 (SEQ ID NO: 1)
MAADGYLPDWLEDNLSEGIREWWDLKPGAPKPK
AAV2 (SEQ ID NO: 2)
MAADGYLPDWLEDTLSEGIRQWWKLKPGPPPPK
AAV3A (SEQ ID NO: 3)
MAADGYLPDWLEDNLSEGIREWWALKPGVPQPK
AAV3B (SEQ ID NO: 4)
MAADGYLPDWLEDNLSEGIREWWALKPGVPQPK
AAV4 (SEQ ID NO: 5)
MTDGYLPDWLEDNLSEGVREWWALQPGAPKPK
AAV5 (SEQ ID NO: 6)
MSFVDHPPDWLEE-VGEGLREFLGLEAGPPKPK
AAV6 (SEQ ID NO: 7)
MAADGYLPDWLEDNLSEGIREWWDLKPGAPKPK
AAV7 (SEQ ID NO: 8)
MAADGYLPDWLEDNLSEGIREWWDLKPGAPKPK
AAV8 (SEQ ID NO: 9)
MAADGYLPDWLEDNLSEGIREWWALKPGAPKPK
AAV9 (SEQ ID NO: 10)
MAADGYLPDWLEDNLSEGIREWWALKPGAPQPK
AAV10 (SEQ ID NO: 11)
MAADGYLPDWLEDNLSEGIREWWDLKPGAPKPK

FIGURE 6B



AAV1 (SEQ ID NO: 1)
AAV2 (SEQ ID NO: 2)
AAV3A (SEQ ID NO: 3)
AAV3B (SEQ ID NO: 4)
AAV4 (SEQ ID NO: 5)
AAV5 (SEQ ID NO: 6)
AAV6 (SEQ ID NO: 7)
AAV7 (SEQ ID NO: 8)
AAV8 (SEQ ID NO: 9)
AAV9 (SEQ ID NO: 10)
AAV10 (SEQ ID NO: 11)

FIGURE 6C



70 80 90
AAV1 (SEQ ID NO: 1) AADAAALEHDKAYDQQLKAGDNPYLRYNHADAE
70 80 90
AAV2 (SEQ ID NO: 2) EADAAALEHDKAYDRQLDSGDNPYLKYNHADAE
70 80 90
AAV3A (SEQ ID NO: 3) EADAAALEHDKAYDQQLKAGDNPYLKYNHADAE
70 80 90
AAV3B (SEQ ID NO: 4) EADAAALEHDKAYDQQLKAGDNPYLKYNHADAE
69 79 89
AAV4 (SEQ ID NO: 5) AADAAALEHDKAYDQQLKAGDNPYLKYNHADAE
69 79 89
AAV5 (SEQ ID NO: 6) RADEVARESHDISYNEQLEAGDNPYLKYNHADAE
70 80 90
AAV6 (SEQ ID NO: 7) AADAAALEHDKAYDQQLKAGDNPYLRYNHADAE
70 80 90
AAV7 (SEQ ID NO: 8) AADAAALEHDKAYDQQLKAGDNPYLRYNHADAE
70 80 90
AAV8 (SEQ ID NO: 9) AADAAALEHDKAYDQQLQAGDNPYLRYNHADAE
70 80 90
AAV9 (SEQ ID NO: 10) AADAAALEHDKAYDQQLKAGDNPYLKYNHADAE
70 80 90
AAV10 (SEQ ID NO: 11) AADAAALEHDKAYDQQLKAGDNPYLRYNHADAE

FIGURE 6D



AAV1 (SEQ ID NO: 1)
AAV2 (SEQ ID NO: 2)
AAV3A (SEQ ID NO: 3)
AAV3B (SEQ ID NO: 4)
AAV4 (SEQ ID NO: 5)
AAV5 (SEQ ID NO: 6)
AAV6 (SEQ ID NO: 7)
AAV7 (SEQ ID NO: 8)
AAV8 (SEQ ID NO: 9)
AAV9 (SEQ ID NO: 10)
AAV10 (SEQ ID NO: 11)

FIGURE 6E



AAV1 (SEQ ID NO: 1)
AAV2 (SEQ ID NO: 2)
AAV3A (SEQ ID NO: 3)
AAV3B (SEQ ID NO: 4)
AAV4 (SEQ ID NO: 5)
AAV5 (SEQ ID NO: 6)
AAV6 (SEQ ID NO: 7)
AAV7 (SEQ ID NO: 8)
AAV8 (SEQ ID NO: 9)
AAV9 (SEQ ID NO: 10)
AAV10 (SEQ ID NO: 11)

FIGURE 6F



AAV1 (SEQ ID NO: 1)
QPAKKRLNFGQTGDSESVPDPQPLGEPPATP-A
AAV2 (SEQ ID NO: 2)
QPARKRLNFGQTGDADSVPDPQPLGQPPAAP-S
AAV3A (SEQ ID NO: 3)
QPARKRLNFGQTGDSESVPDPQPLGEPPAAP-T
AAV3B (SEQ ID NO: 4)
QPARKRLNFGQTGDSESVPDPQPLGEPPAAP-T
AAV4 (SEQ ID NO: 5)
QPAKKKLVFE---DETGAGDGPPEGSTSGA--M
AAV5 (SEQ ID NO: 6)
KPST-------SSDAEAGPSGSQQLQIPAQPAS
AAV6 (SEQ ID NO: 7)
QPAKKRLNFGQTGDSESVPDPQPLGEPPATP-A
AAV7 (SEQ ID NO: 8)
QPARKRLNFGQTGDSESVPDPQPLGEPPAAP-S
AAV8 (SEQ ID NO: 9)
QPARKRLNFGQTGDSESVPDPQPLGEPPAAP-S
AAV9 (SEQ ID NO: 10)
QPAKKRLNFGQTGDTESVPDPQPIGEPPAAP-S
AAV10 (SEQ ID NO: 11)
QPAKKRLNFGQTGESESVPDPQPIGEPPAGP-S

FIGURE 6G



200
210
220
230
198
208
218
228
AAV1 (SEQ ID NO: 1) AVGPTTMASGGGAPMADNNEGADGVGNASGNWH
AAV2 (SEQ ID NO: 2) GLGTNTMATGSGAPMADNNEGADGVGNSSGNWH
AAV3A (SEQ ID NO: 3) SLGSNTMASGGGAPMADNNEGADGVGNSSGNWH
AAV3B (SEQ ID NO: 4) SLGSNTMASGGGAPMADNNEGADGVGNSSGNWH
193
203
212
222
AAV4 (SEQ ID NO: 5) SDDSEMRAAAGGAAV-EGGQGADGVGNASGDWH
188
198
208
218
AAV5 (SEQ ID NO: 6) SLGADTMSAGGGGPLGDNNQGADGVGNASGDWH
AAV6 (SEQ ID NO: 7) AVGPTTMASGGGAPMADNNEGADGVGNASGNWH
199
209
219
229
AAV7 (SEQ ID NO: 8) SVGSGTVAAGGGAPMADNNEGADGVGNASGNWH
AAV8 (SEQ ID NO: 9) GVGPNTMAAGGGAPMADNNEGADGVGSSSGNWH
AAV9 (SEQ ID NO: 10) GVGSLTMASGGGAPVADNNEGADGVGSSSGNWH
AAV10 (SEQ ID NO: 11) GLGSGTMAAGGGAPMADNNEGADGVGSSSGNWH

FIGURE 6H



240
238
250
248
260
258
AAV1 (SEQ ID NO: 1) CDSTWLGDRVITTSTRTWALPTYNNHLYKQISS
AAV2 (SEQ ID NO: 2) CDSTWMGDRVITTSTRTWALPTYNNHLYKQISS
AAV3A (SEQ ID NO: 3) CDSQWLGDRVITTSTRTWALPTYNNHLYKQISS
AAV3B (SEQ ID NO: 4) CDSQWLGDRVITTSTRTWALPTYNNHLYKQISS
232
242
252
AAV4 (SEQ ID NO: 5) CDSTWSEGHVTTTSTRTWVLPTYNNHLYKRLGE
228
238
248
AAV5 (SEQ ID NO: 6) CDSTWMGDRVVTKSTRTWVLPSYNNHQYREIKS
238
248
258
AAV6 (SEQ ID NO: 7) CDSTWLGDRVITTSTRTWALPTYNNHLYKQISS
239
249
259
AAV7 (SEQ ID NO: 8) CDSTWLGDRVITTSTRTWALPTYNNHLYKQISS
AAV8 (SEQ ID NO: 9) CDSTWLGDRVITTSTRTWALPTYNNHLYKQISN
238
248
258
AAV9 (SEQ ID NO: 10) CDSQWLGDRVITTSTRTWALPTYNNHLYKQISN
239
249
259
AAV10 (SEQ ID NO: 11) CDSTWLGDRVITTSTRTWALPTYNNHLYKQISN

FIGURE 6I



SUBSTITUTE SHEET (RULE 26)

FIGURE 6J





AAV1 (SEQ ID NO: 1)
AAV2 (SEQ ID NO: 2)
AAV3A (SEQ ID NO: 3)
AAV3B (SEQ ID NO: 4)
AAV4 (SEQ ID NO: 5)
AAV5 (SEQ ID NO: 6)
AAV6 (SEQ ID NO: 7)
AAV7 (SEQ ID NO: 8)
AAV8 (SEQ ID NO: 9)
AAV9 (SEQ ID NO: 10)
AAV10 (SEQ ID NO: 11)

FIGURE 6K




SUBSTITUTE SHEET (RULE 26)

FIGURE 6L




SUBSTITUTE SHEET (RULE 26)

FIGURE 6M




SUBSTITUTE SHEET (RULE 26)

FIGURE 6N



SUBSTITUTE SHEET (RULE 26)

FIGURE 6O



SUBSTITUTE SHEET (RULE 26)

FIGURE 6P




AAV1 (SEQ ID NO: 1)
VSKTKTDN-----NNSNFTWTGASKYNLNGRZS
AAV2 (SEQ ID NO: 2)
VSKTSADN-----NNSZYSWTGATKYHLNGRDS
AAV3A (SEQ ID NO: 3)
LSKTANDN-----NNSNFPWTAASKYHLNGRDS
AAV3B (SEQ ID NO: 4)
LSKTANDN-----NNSNFPWTAASKYHLNGRDS
AAV4 (SEQ ID NO: 5)
FSKTANQNYKIPATGSDSLIKYZTHSTLDGRWS
AAV5 (SEQ ID NO: 6)
WNLGSGVNR-----ASVSAFATTNRMELZGASY
AAV6 (SEQ ID NO: 7)
VSKTKTDN-----NNSNFTWTGASKYNLNGRZS
AAV7 (SEQ ID NO: 8)
VSKTLDQN-----NNSNFAWTGATKYHLNGRNS
AAV8 (SEQ ID NO: 9)
VSTTTGQN-----NNSNFAWTAGTKYHLNGRNS
AAV9 (SEQ ID NO: 10)
VSTTVTQN-----NNSZFAWPGASSWALNGRNS
AAV10 (SEQ ID NO: 11)
VSTTLSQN-----NNSNFAWTGATKYHLNGRDS

FIGURE 6Q



SUBSTITUTE SHEET (RULE 26)

FIGURE 6R



570
580
590
556
565
575
AAV1 (SEQ ID NO: 1) GASNTAL--DNVMITDEEEIKATNPVATERFGT
555
564
574
AAV2 (SEQ ID NO: 2) EKTNVDI--EKVMITDEEEIRTTNPVATEQYGS
556
565
575
AAV3A (SEQ ID NO: 3) TASNAEL--DNVMITDEEEIRTTNPVATEQYGT
556
565
575
AAV3B (SEQ ID NO: 4) TASNAEL--DNVMITDEEEIRTTNPVATEQYGT
554
563
573
AAV4 (SEQ ID NO: 5) GNTATVP--GTLIFTSEEELAATNATDTDMWGN
544
554
564
AAV5 (SEQ ID NO: 6) PGTTATYLEGNMLITSESETQPVNRVAYNVGGQ
556
565
575
AAV6 (SEQ ID NO: 7) GASNTAL--DNVMITDEEEIKATNPVATERFGT
557
566
576
AAV7 (SEQ ID NO: 8) TNKTTL---ENVLMTNEEEIRPTNPVATEEYGI
558
567
577
AAV8 (SEQ ID NO: 9) ARDNADY--SDVMLTSEEEIKTTNPVATEEYGI
556
565
575
AAV9 (SEQ ID NO: 10) GRDNVDA--DKVMITNEEEIKTTNPVATESYGQ
558
567
577
AAV10 (SEQ ID NO: 11) GRDNVDY--SSVMLTSEEEIKTTNPVATEQYGV

FIGURE 6S



600
610
620
585
595
605
AAV1 (SEQ ID NO: 1) VAVNFQSSSTDPATGDVHAMGALPGMVWQDRDV
584
594
604
AAV2 (SEQ ID NO: 2) VSTNLQRGNRQAATADVNTQGVLPGMVWQDRDV
585
595
605
AAV3A (SEQ ID NO: 3) VANNLQSSNTAPTTGTVNHQGALPGMVWQDRDV
585
595
605
AAV3B (SEQ ID NO: 4) VANNLQSSNTAPTTRTVNDQGALPGMVWQDRDV
583
593
603
AAV4 (SEQ ID NO: 5) LPGGDQSNSNLPTVDRLTALGAVPGMVWQNRDI
574
584
594
AAV5 (SEQ ID NO: 6) MATNNQSSTTAPATGTYNLQEIVPGSVWMERDV
585
595
605
AAV6 (SEQ ID NO: 7) VAVNLQSSSTDPATGDVHVMGALPGMVWQDRDV
586
596
606
AAV7 (SEQ ID NO: 8) VSSNLQAANTAAQTQVVNNQGALPGMVWQNRDV
587
597
607
AAV8 (SEQ ID NO: 9) VADNLQQQNTAPQIGTVNSQGALPGMVWQNRDV
585
595
605
AAV9 (SEQ ID NO: 10) VATNHQSAQAQAQTGWVQNQGILPGMVWQDRDV
587
597
607
AAV10 (SEQ ID NO: 11) VADNLQQANTGPIVGNVNSQGALPGMVWQNRDV

FIGURE 6T





630
640
650
660
615
625
635
645
AAV1 (SEQ ID NO: 1) YLQGPIWAKIPHTDGHFHPSPLMGGFGLKNPPP
614
624
634
644
AAV2 (SEQ ID NO: 2) YLQGPIWAKIPHTDGHFHPSPLMGGFGLKHPPP
615
625
635
645
AAV3A (SEQ ID NO: 3) YLQGPIWAKIPHTDGHFHPSPLMGGFGLKHPPP
615
625
635
645
AAV3B (SEQ ID NO: 4) YLQGPIWAKIPHTDGHFHPSPLMGGFGLKHPPP
613
623
633
643
AAV4 (SEQ ID NO: 5) YYQGPIWAKIPHTDGHFHPSPLIGGFGLKHPPP
604
614
624
634
AAV5 (SEQ ID NO: 6) YLQGPIWAKIPETGAHFHPSPAMGGFGLKHPPP
615
625
635
645
AAV6 (SEQ ID NO: 7) YLQGPIWAKIPHTDGHFHPSPLMGGFGLKHPPP
616
626
636
646
AAV7 (SEQ ID NO: 8) YLQGPIWAKIPHTDGNFHPSPLMGGFGLKHPPP
617
627
637
647
AAV8 (SEQ ID NO: 9) YLQGPIWAKIPHTDGNFHPSPLMGGFGLKHPPP
615
625
635
645
AAV9 (SEQ ID NO: 10) YLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPP
617
627
637
647
AAV10 (SEQ ID NO: 11) YLQGPIWAKIPHTDGNFHPSPLMGGFGLKHPPP

FIGURE 6U




SUBSTITUTE SHEET (RULE 26)

FIGURE 6V



SUBSTITUTE SHEET (RULE 26)

FIGURE 6W


730
715
740
725
750
752
737
AAV1 (SEQ ID NO: 1) DFTVDNNGLYTEPRPIGTRYLTRPL
714
724
736
AAV2 (SEQ ID NO: 2) DFTVDTNGVYSEPRPIGTRYLTRNL
715
725
736
AAV3A (SEQ ID NO: 3) DFTVDTNGVYSEPRPIGTRYLTRNL
715
725
736
AAV3B (SEQ ID NO: 4) DFTVDTNGVYSEPRPIGTRYLTRNL
713
723
735
AAV4 (SEQ ID NO: 5) LWAPDAAGKYTEPRAIGTRYLTHHL
703
713
725
AAV5 (SEQ ID NO: 6) DFAPDSTGEYRTTRPIGTRYLTRPL
715
725
737
AAV6 (SEQ ID NO: 7) DFTVDNNGLYTEPRPIGTRYLTRPL
716
726
738
AAV7 (SEQ ID NO: 8) DFAVDSQGVYSEPRPIGTRYLTRNL
717
727
739
AAV8 (SEQ ID NO: 9) DFAVNTEGVYSEPRPIGTRYLTRNL
715
725
737
AAV9 (SEQ ID NO: 10) EFAVNTEGVYSEPRPIGTRYLTRNL
717
727
738
AAV10 (SEQ ID NO: 11) DFAVNTEGTYSEPRPIGTRYLTRNL




FIGURE 7




FIGURE 8




FIGURE 9



Anti-GFP/M-L Opsin/DAPI
RPE layer
Artificial separation of RPE layer
GC layer
50 µm
Anti-GFP
M-L Opsin
50 µm

FIGURE 10A






FIGURE 10C





FIGURE 10B

FIGURE 10D


EGFP/Anti-GFP/ M-L Opsin/DAPI
RPE layer
Foveola
RGC layer
50 µm
EGFP/Anti-GFP/ M-L Opsin/DAPI
Fovea
10 µm
EGFP
Anti-GFP
M-L Opsin
EGFP
Anti-GFP
M-L Opsin



EGFP
RPE layer
RGC layer
100 μm
EGFP
100 μm
RPE layer
RGC layer

FIGURE 10E




FIGURE 11A

FIGURE 11B

FIGURE 11C






FIGURE 11D



SUBSTITUTE SHEET (RULE 26)

FIGURE 11E


variant
AAV2
GFP/GAPDH
1.25
1
0.75
0.5
0.25
0
MOI
ECL Exp.
5000
30
5000
120
5000
300
500
300
500
30
500
300
500
120
500
300
FB-iPSC RPE
5000
30
5000
300
500
3
500
30
500
300
ESI-017 RPE
MOI 500
-Ctrl
variant
AAV2
GADPH
GFP
ECL Exp. 300 s
MOI 5000
-Ctrl
variant
AAV2
ECL Exp. 30 s




FIGURE 12A FIGURE 12B FIGURE 12C FIGURE 12D




FIGURE 12E




FIGURE 12F



mock
GFP
AFLB
SC-RNBZ HL
SC-RNBZ LH2
SC-RNBZ LH1
Anti-VEGF (ug/ml)
0
2
4
6
8
10
12
14
16
18
20

FIGURE 13A



Anti-VEGF (ug/ml)
0
5
10
15
20
25
30
35
40
45
50
55
60
CRP
AFLB
SS-RNBZ LH1

FIGURE 13B



98
62
49
38
28
17
Lucentis
sc-RNBZ HL
sc-RNBZ LH1
sc-RNBZ LH2
AFLB
GFP
mock
Eylea

FIGURE 14A



anti-Fc
AFLB
GFP
Eylea
anti-Fc
sc-RNBZ LH
Lucentis
BRO
97
64
51
39
28
19
97
64
51
39
28
19

FIGURE 14B



Eylea
Mock
GFP
ANG
Luscntis
sc'RNB2 HW
sc'RNB2 LH1
sc'RNB2 LH2
1,000.0
100.0
10.0
1.0
0.1
Anti-VEGF (pM)
18.0
16.0
14.0
12.0
10.0
8.0
6.0
4.0
2.0
0.0
VEGF (pM)

FIGURE 15A



VEGF (pM)
18
16
14
12
10
8
6
4
2
0
Anti-VEGF (dilution fold)
10,000,000
1,000,000
100,000
10,000
1,000
100
10
GRB
AFLB
RMBZ1M
BRO

FIGURE 15B



Eylea
ARLB
Lucentis
sc-rhuBz
Anti-VEGF (ng/ml)
1,000
100
10
1
RLU
110,000
100,000
90,000
80,000
70,000
60,000
50,000
40,000
30,000
20,000
10,000
0

FIGURE 16



100,000
90,000
80,000
70,000
60,000
50,000
40,000
30,000
20,000
10,000
RLU
1,000
100
10
dilution
GFP
AFLB
scFvMBZ HL
scFvMBZ LH1

FIGURE 17A



Anti-VEGF (dilution fold)
1
10
100
1,000
10,000
RLU
100,000
90,000
80,000
70,000
60,000
50,000
40,000
30,000
20,000
sc-AN827 LH
APL8
Gra
BRO

FIGURE 17B



6,000
5,000
4,000
3,000
2,000
1,000
0
VEGF (pg/ml)
mock
GFP
AFLB
sc-RNBZ HL
sc-RNBZ LH2

FIGURE 18


VEGFr (pg/ml)
9,000
8,000
7,000
6,000
5,000
4,000
3,000
2,000
1,000
0
AF1.9
sc-9027 H1
sc-9027 H2
day 10
day 19

FIGURE 19



Anti-VEGF (ng/ml)
3,500
3,000
2,500
2,000
1,500
1,000
500
0
day 10
day 6
AFL8
sc-RN8Z HL
BRO
scFp

FIGURE 20





day
6 10
BRO
Lucentis
sc-RNBZ
HL LH
6 10 6 10
Anti-Fab
105
85
58
48
28
20
16
14
10
GFP AFLB
6 10 6 10
Eylea
Anti-Fc
105
85
58
48
28
20
16
14
10

FIGURE 21

FIGURE 22


day 6
AFLB
sc-RNBZ HL
sc-RNBZ LH
BRO
GFP
20
18
16
14
12
10
8
6
4
2
0
1,000,000
100,000
10,000
1,000
100
10
dilution fold
MFI (log)


day 10
AFLB
sc-RNBZ HL
sc-RNBZ LH
BRO
GFP
20
18
16
14
12
10
8
6
4
2
0
1,000,000
100,000
10,000
1,000
100
10
dilution fold
MFI (log)



day 6
day 9
AFLIB
sc-RMBZ HL
sc-RMBZ LH
BRO
GRP
100
10
1,000
Anti-VEGF (dilution fold)
RLU
100,000
90,000
80,000
70,000
60,000
50,000
40,000
30,000
20,000
1

FIGURE 23